Y150

Y150 is a bispecific antibody designed to target both CD38 and CD3. It functions as a bispecific T-cell engager (BiTE), binding to the CD38 antigen on multiple myeloma cells and the CD3 receptor on T cells, thereby redirecting T cell cytotoxicity toward malignant plasma cells. The drug is being developed primarily for the treatment of relapsed or refractory multiple myeloma, with additional potential indications in other lymphoproliferative disorders and precursor T-cell lymphoblastic leukemia-lymphoma. The developer is Wuhan YZY Biopharma, with clinical trials conducted in China. As of March 2025, its highest development phase was Phase 1, but this status has been reported as suspended.

Other names

Y-150Y150Y 150